Category: by journal

Former University of Maryland cancer researcher up to 21 retractions

Anil Jaiswal

Anil Jaiswal, who until a year ago was a cancer researcher at the University of Maryland, Baltimore, has had four more papers retracted.

That makes 21 for Jaiswal, who joins our leaderboard of the 30 researchers with the most retractions. All four new retractions appear in journals published by the American Association for Cancer Research, and are for image or data manipulation.

For example, here’s the retraction notice for “Aromatase Inhibitor–mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer,” in Molecular Cancer Therapeutics: Continue reading Former University of Maryland cancer researcher up to 21 retractions

JAMA journal retracts paper when author can’t produce original data

In July 2017, a JAMA journal called for an investigation into a 2013 paper it had published after concluding that the article had “scientific and ethical concerns.” Now the journal, JAMA Otolaryngology − Head & Neck Surgery, is retracting the paper.

The article, “Dexamethasone for the prevention of recurrent laryngeal nerve palsy and other complications after thyroid surgery: a randomized double-blind placebo-controlled trial,” came from a group in Italy led by Mario Schietroma, of the Department of Surgery at the University of L’Aquila, in Abruzzo, Italy. Schietroma, who in December admitted to us that a retracted 2015 paper of his in the Journal of the American College of Surgeons suffered from “misinterpretation of the statistical data,” now has four retractions.

The paper has been cited a total of 18 times, according to Clarivate Analytics’ Web of Science, including twice since it was subjected to an expression of concern. One of those citations was by a Cochrane systematic review.

According to the retraction notice: Continue reading JAMA journal retracts paper when author can’t produce original data

“Sufficiently serious” issues in study prompt company to yank drug approval application in China

The maker of a leading over-the-counter antacid has withdrawn its application for approval of the drug in China because a clinical trial of the product in that country was marred by “major protocol deviations.”

Researchers for the company, Reckitt Benckiser, maker of Gaviscon, had published a report on the study in 2015 in the journal Alimentary Pharmacology & Therapeutics. But the journal has now retracted the article, “Randomised clinical trial: The clinical efficacy and safety of an alginate‐antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China,” at the behest of the drug maker.

According to the notice: Continue reading “Sufficiently serious” issues in study prompt company to yank drug approval application in China

University of Kentucky cancer toxicologist retracts three papers for image duplication

Xianglin Shi

A researcher at the University of Kentucky who studies the cancer risks of toxic chemicals has retracted three papers.

All of the retraction notices, which appear in the Journal of Biological Chemistry, refer to some kind of image duplication. The papers were originally published between 2014 and 2017, with the 2014 paper cited 39 times, according to Clarivate Analytics’ Web of Science.

Continue reading University of Kentucky cancer toxicologist retracts three papers for image duplication

A paper from the Jockey Club School makes a false start

Here’s a head-scratcher from the Journal of Affective Disorders, which has retracted a 2017 article for, well, reasons we invite you to divine.

The article, “The effectiveness of group-based behavioral activation in the treatment of depression: An updated meta-analysis of randomized controlled trial,” was published by a group at the Jockey Club School of Public Health and Primary Care, part of the the Chinese University of Hong Kong.

According to the retraction notice: Continue reading A paper from the Jockey Club School makes a false start

Journal flags papers, saying authors didn’t adequately disclose ties to Monsanto

A toxicology journal has issued an expression of concern for a group of papers about the controversial herbicide glyphosate after concluding that some of the authors didn’t adequately disclose their ties to the maker of the product.

At issue are five articles that appeared in a 2016 supplement to Critical Reviews in Toxicology, a Taylor & Francis title, about the chemical, the active ingredient in Monsanto’s blockbuster weed-killer Roundup. Although the authors of the articles don’t overlap perfectly, Keith Solomon, of the University of Guelph, in Canada, appears on three of the articles; Gary Williams, of New York Medical College, appears on three as well.

Williams was caught up in a ghost-writing scandal after court documents revealed that he had put his name on a published paper written by Monsanto employees. Solomon served on a panel funded by Monsanto that undercut the conclusions of a report from the World Health Organization that glyphosate is probably cancerous to people.

According to the expression of concern, which was first reported by Bloomberg today:    Continue reading Journal flags papers, saying authors didn’t adequately disclose ties to Monsanto

“Irreconcilable” differences about author order, other issues topple two articles in Spandidos journal

Researchers in China have retracted a pair of papers in the same journal after running into “irreconcilable” differences with the articles.

Both articles appeared in Molecular Medicine Reports, from Spandidos.

One article, “Combined treatment with extracorporeal shock‑wave therapy and bone marrow mesenchymal stem cell transplantation improves bone repair in a rabbit model of bone nonunion,” published in November 2017, suffered from, well, serious nonunion: Continue reading “Irreconcilable” differences about author order, other issues topple two articles in Spandidos journal

Journal reverses retractions, says apparent citation manipulation was “an innocent and honest mistake”

A journal that retracted three papers earlier this year because of concerns that one of the authors had asked conference presenters to cite them has republished the articles, saying that it has “inconclusive evidence of improper behavior.”

In February, we reported that the Journal of Vibroengineering had retracted three papers by Magd Abdel Wahab, of Ghent University in Belgium. Wahab had chaired a recent conference, and as we reported then, almost three-quarters of papers that cited Wahab’s three papers originated from the conference. Journal editor Minvydas Ragulskis told us that was “large enough to assume a high probability for citation manipulation.”

At the time, Wahab told us the papers would be republished. And it turns that they were, not long after our original post. There is no explanation on the papers themselves, just a “Republished Paper” in front of the three titles, and an editorial note that is not linked, as best we can tell, from any of the papers.

Along with the citation data the investigation was based on, that note explains that: Continue reading Journal reverses retractions, says apparent citation manipulation was “an innocent and honest mistake”

Four years after readers raise concerns, journal finally retracts climate paper

The wheels of scientific publishing turn slowly … but they do (sometimes) turn.

In January, we reported on the case of a paper on global warming marred by several problems, including allegations of plagiarism and “false claims” by the authors — which readers had raised as early as 2014, with no result. (Find a discussion of those allegations here.)

Now, the journal, Elsevier’s Renewable and Sustainable Energy Reviews (ironic on multiple levels, when you think about it), is retracting the paper.

According to the long-time-in-coming retraction notice: Continue reading Four years after readers raise concerns, journal finally retracts climate paper

Researcher who once tried to sue critics has another dozen papers retracted

Fazlul Sarkar

A cancer researcher who went to court — unsuccessfully — claiming that commenters on PubPeer had cost him a new job has just lost another 12 papers.

The twelve now-retracted papers by Fazlul Sarkar and colleagues — as well as another by Sarkar that is now subject to an editor’s note — all appeared in Cancer Research, which made for a long table of contents in its September 15 issue. Continue reading Researcher who once tried to sue critics has another dozen papers retracted